Glenmark Generics Inc (GGI), a step down subsidiary of Glenmark Pharmaceuticals has received US market approval and introduction of Trandolapril & Verapamil Hydrochloride (HCI) Extended Release Tablets, the generic equivalent of AbbVie, Inc.’s TARKA.
TARKA is indicated for the treatment of hypertension. According to IMS Health sales data for the 12 month period ending December 2014, TARKA achieved annual sales of approximately $23.5 million.
Glenmark will commence distribution of Trandolapril & Verapamil HCI Tablets immediately, which will be available in 1mg/240mg, 2mg/180mg, 2mg/240mg and 4mg/240mg strengths.
Glenmark’s current portfolio consists of 95 products authorized for distribution in the US marketplace and 74 ANDA’s pending approval with the USFDA. In addition to these internal filings, GGI continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: